Efficacy of Quetiapine in Parkinson's Psychosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN74681449

Enrollment

Registered

2005-09-09

Start date

2005-08-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease Nervous System Diseases Parkinson's disease

Interventions

Quetiapine versus Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hallucinations, delusions of a severity >3/7 on the Brief Psychiatric Rating Scale, 2. Diagnosis of Parkinson's which meets UKPD Society Brain Bank criteria

Exclusion criteria

Exclusion criteria: 1. Anti-psychotic medication in the preceding 3 months 2. Any contra-indication to quetiapine 3. Any important drug interactions 4. Major concomitant medical illness 5. History of uncontrolled diabetes or hypertension 6. Changes in medication in the last 14 days

Design outcomes

Primary

Measure	Time frame
1. Improvment in psychotic symptoms 2. Parkinsonian symptoms 3. Depressive symptoms 4. Remaining in the trial for the 12 week duration (patients will be withdrawn if their psychotic symptoms worsen)	—

Secondary

Measure	Time frame
1. Activities of daily living 2. Cognitive function 3. Carer burden	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026